| 大肠癌的分子靶向治疗 |
| |
| 引用本文： | 盛莉莉,吉兆宁. 大肠癌的分子靶向治疗[J]. 金属学报, 2013, 18(6): 715-720 |
| |
| 作者姓名： | 盛莉莉 吉兆宁 |
| |
| 作者单位： | 安徽省皖南医学院附属弋矶山医院,芜湖 241000,安徽 |
| |
| 摘 要： | 大肠癌是最常见的恶性肿瘤之一,晚期大肠癌的治疗主要依靠氟尿嘧啶类、草酸铂和伊立替康等药物为主的化疗,但易产生耐药性。近年来靶向治疗的成功应用提高了晚期大肠癌患者的生存率。本文就目前大肠癌的靶向治疗方面进行综述。
|
| 关 键 词： | 大肠癌 靶向治疗 贝伐珠单克隆抗体 西妥昔单克隆抗体 帕尼单克隆抗体 |
| 收稿时间： | 2012-09-18 |
| 修稿时间： | 2013-01-07 |
Molecular targeted therapy of colorectal cancer |
| |
| SHENG Li-li,JI Zhao-ning. Molecular targeted therapy of colorectal cancer[J]. Acta Metallurgica Sinica, 2013, 18(6): 715-720 |
| |
| Authors: | SHENG Li-li JI Zhao-ning |
| |
| Affiliation: | Yijishan Hospital of Wannan Medical College, Wuhu 241000, Anhui, China |
| |
| Abstract: | Colorectal cancer is one of the most common malignant tumors. For patients with metastatic colorectal cancer (mCRC), chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan is the main treatment, but multi-drug resistance occurs very often. In recent years the successful development of targeted therapy improves survival in patients with mCRC. This article reviews the development of targeted agents for the treatment of mCRC. |
| |
| Keywords: | Colorectal cancer Targeted therapy Bevacizumab Cetuximab Panitumumab |
|
| 点击此处可从《金属学报》浏览原始摘要信息 |
|
点击此处可从《金属学报》下载全文 |
